Opendata, web and dolomites



Total Cost €


EC-Contrib. €






 LUPUSCARE project word cloud

Explore the words cloud of the LUPUSCARE project. It provides you a very rough idea of what is the project "LUPUSCARE" about.

constituents    trials    autoimmunity    extends    omics    stem    diverse    patients    animal    innovative    technologies    microbiota    whereby    lupus    therapy    data    record    genetic    molecular    epigenetic    homeostasis    interplay    severity    risk    characterization    biological    clinical    editing    environmental    elucidated    track    genomics    networks    elaborate    diagnosis    combination    gender    maintains    marrow    cell    paradigm    matrices    150    initial    female    family    device    genome    staggering    unifying    foundations    ask    mutations    pathogenesis    laid    disease    hypothesis    tissue    heterogeneous    experimental    systemic    fundamental    bone    sequencing    biology    culminating    glimpse    self    epigenomic    abnormalities    models    immunotherapy    organ    personalized    validate    correlation    genomic    predominance    therapeutic    originate    taxonomy    allowed    hscs    utility    cells    insights    recognizes    trial    perturbation    single    mechanism    somatic    monitoring    rna    throughput    lymphoma    erythematosus    pursuing    hyperactivity    profile    impacts    expression    diagnostics    humanized    sle    participate    trios    gene    panels    boundaries    chip    examine    varying    phenotypes    systematic    lie    pathogenetic    questions    immune    integrate    hematopoietic    trait    shift   

Project "LUPUSCARE" data sheet

The following table provides information about the project.


Organization address
city: ATHINA
postcode: 115 27

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 2˙355˙000 €
 EC max contribution 2˙355˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Systemic lupus erythematosus (SLE) is a heterogeneous disease whereby an interplay of environmental, genetic and epigenetic factors lead to perturbation of complex biological networks culminating into diverse clinical phenotypes of varying severity. High throughput methods have allowed an “initial glimpse” into pathogenesis and have laid the foundations for a molecular-based taxonomy for personalized therapy. Based on our experience with the molecular characterization of SLE, a recently completed RNA sequencing analysis of 150 patients, and our track- record of “paradigm shift” trials in SLE, we will integrate data from multi-tissue analyses with novel technologies to improve its diagnosis, monitoring and therapy, and ask fundamental pathogenetic questions in systemic autoimmunity. More specifically, we will design gene expression panels and “expression profile”/”clinical trait” correlation matrices for diagnostics, personalized immunotherapy and improved clinical trial design. In a systematic multi-tissue approach, we will examine the role of somatic mutations in enhancing immune hyperactivity and the risk for lymphoma. The staggering (7-9:1) female predominance will be elucidated through elaborate genomic, epigenomic and microbiota analyses of family trios. Finally, we will be pursuing the innovative hypothesis that the fundamental abnormalities of SLE lie within the bone marrow hematopoietic stem cells (HSCs) - from which all cells that participate in the pathogenesis of SLE originate - and establish it as a unifying pathogenetic mechanism. By a combination of novel experimental analyses with single cell genomics, multi–omics, humanized animal models, genome editing and an “organ on-a-chip” device, we will validate HSCs as a therapeutic target. The utility of SLE research extends beyond its boundaries, by providing unique insights as to how the immune system recognizes self-constituents and maintains its homeostasis, and how gender impacts on disease biology.


year authors and title journal last update
List of publications.
2019 Grigoriou Maria
RNA-sequencing and transcriptome analysis of hematopoietic stem cells in systemic lupus erythematosus
published pages: , ISSN: , DOI:
2019 Nikolaos I Panousis, George K Bertsias, Halit Ongen, Irini Gergianaki, Maria G Tektonidou, Maria Trachana, Luciana Romano-Palumbo, Deborah Bielser, Cedric Howald, Cristina Pamfil, Antonis Fanouriakis, Despoina Kosmara, Argyro Repa, Prodromos Sidiropoulos, Emmanouil T Dermitzakis, Dimitrios T Boumpas
Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
published pages: 1079-1089, ISSN: 0003-4967, DOI: 10.1136/annrheumdis-2018-214379
Annals of the Rheumatic Diseases 78/8 2020-04-15
2020 D Nikolopoulos, M Kostopoulou, A Pieta, T Karageorgas, D Tseronis, K Chavatza, S Flouda, P Rapsomaniki, A Banos, E Kremasmenou, V Tzavara, P Katsimbri, A Fanouriakis, D T Boumpas
Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort
published pages: 96120332090893, ISSN: 0961-2033, DOI: 10.1177/0961203320908932
Lupus 2020-03-11
2019 Maria Grigoriou, Aggelos Banos, Anastasia Filia, Pavlos Pavlidis, Stavroula Giannouli, Vassiliki Karali, Dionysis Nikolopoulos, Antigone Pieta, George Bertsias, Panayotis Verginis, Ioannis Mitroulis, Dimitrios T Boumpas
Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
published pages: annrheumdis-2019, ISSN: 0003-4967, DOI: 10.1136/annrheumdis-2019-215782
Annals of the Rheumatic Diseases 2020-01-30
2018 Katerina Gkirtzimanaki, Eleni Kabrani, Dimitra Nikoleri, Alexander Polyzos, Athanasios Blanas, Prodromos Sidiropoulos, Antonis Makrigiannakis, George Bertsias, Dimitrios T. Boumpas, Panayotis Verginis
IFNα Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion
published pages: 921-933.e5, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2018.09.001
Cell Reports 25/4 2019-04-16
2018 E.A.A. Christou, A. Banos, D. Kosmara, GK Bertsias, DT Boumpas
Sexual dimorphism in SLE: above and beyond sex hormones
published pages: 3-10, ISSN: 0961-2033, DOI: 10.1177/0961203318815768
Lupus 28/1 2019-02-25
2018 Eleni Frangou, Akrivi Chrysanthopoulou, Alexandros Mitsios, Konstantinos Kambas, Stella Arelaki, Iliana Angelidou, Athanasios Arampatzioglou, Hariklia Gakiopoulou, George K Bertsias, Panayotis Verginis, Konstantinos Ritis, Dimitrios T Boumpas
REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)
published pages: annrheumdis-2018, ISSN: 0003-4967, DOI: 10.1136/annrheumdis-2018-213181
Annals of the Rheumatic Diseases 2019-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUPUSCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUPUSCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VARME (2019)

Varieties of Media Effects

Read More  

MIX2FIX (2019)

Hybrid, organic-inorganic chalcogenide optoelectronics

Read More  

IMPACCT (2019)

Improved Patient Care by Combinatorial Treatment

Read More